Christopher W. Cunningham

Dr. Christopher W. Cunningham

Concordia University Wisconsin, Mequon, United States

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2018 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
SBS. Mallory Burns
S. Mallory Burns
Christopher W. CunninghamChristopher W. Cunningham
Christopher W. Cunningham
SMSusan L. Mercer
Susan L. Mercer

14 May 2018 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
ADAndrea L. Devereaux
Andrea L. Devereaux
SMSusan L. Mercer
Susan L. Mercer
Christopher W. CunninghamChristopher W. Cunningham
Christopher W. Cunningham

1 June 2019 in Neuropharmacology
Verified
Journal Article
Closed access
Christopher W. CunninghamChristopher W. Cunningham
Christopher W. Cunningham
WEWaleed M. Elballa
Waleed M. Elballa
SVStephanie U. Vold
Stephanie U. Vold

1 January 2017
Verified
Book Chapter
Closed access
CHCecilia Hillard
Cecilia Hillard
HHHuan Huang
Huan Huang
CVCaleb D. Vogt
Caleb D. Vogt
BRBeatriz E. Rodrigues
Beatriz E. Rodrigues
TNTerrence S. Neumann
Terrence S. Neumann
Christopher W. CunninghamChristopher W. Cunningham
Christopher W. Cunningham

14 June 2023 in Journal of the American Chemical Society
Verified
Journal Article
Open access
SKSara E. Kearney
Sara E. Kearney
AGAnghelo J. Gangano
Anghelo J. Gangano
DBDaniel G. Barrus
Daniel G. Barrus
KRKyle J. Rehrauer
Kyle J. Rehrauer
TRTerry-Elinor R. Reid
Terry-Elinor R. Reid
AGAlexander J. Grenning
Alexander J. Grenning
The resorcinol-terpene phytocannabinoid template is a privileged scaffold for the development of diverse therapeutics targeting the endocannabinoid system. Axially chiral cannabinols (axCBNs) are unnatural cannabinols (CBNs) that bear an additional C10 substituent, which twists the cannabinol biaryl framework out of planarity creating an axis of chirality. This unique structural modification is hypothesized to enhance both the physical and biological properties of cannabinoid ligands, thus ushering in the next generation of endocannabinoid system chemical probes and cannabinoid-inspired leads for drug development. In this full report, we describe the philosophy guiding the design of axCBNs as well as several synthetic strategies for their construction. We also introduce a second class of axially chiral cannabinoids inspired by cannabidiol (CBD), termed axially chiral cannabidiols (axCBDs). Finally, we provide an analysis of axially chiral cannabinoid (axCannabinoid) atropisomerism, which spans two classes (class 1 and 3 atropisomers), and provide first evidence that axCannabinoids retain─and in some cases, strengthen─affinity and functional activity at cannabinoid receptors. Together, these findings present a promising new direction for the design of novel cannabinoid ligands for drug discovery and exploration of the complex endocannabinoid system.

20 October 2023 in Pharmacological Research
Verified
Journal Article
Open access
KRKyle J. Rehrauer
Kyle J. Rehrauer
Christopher W. CunninghamChristopher W. Cunningham
Christopher W. Cunningham
Though efficacious in managing chronic, severe pain, opioid analgesics are accompanied by significant adverse effects including constipation, tolerance, dependence, and respiratory depression. The life-threatening risks associated with µ opioid receptor agonist-based analgesics challenges their use in clinic. A rational approach to combatting these adverse effects is to develop agents that incorporate activity at a second pharmacologic target in addition to µ opioid receptor activation. The promise of such bivalent or bifunctional ligands is the development of an analgesic with an improved side effect profile. In this review, we highlight ongoing efforts in the development of bivalent and bifunctional analgesics that combine µ agonism with efficacy at κ and δ opioid receptors, the nociceptin opioid peptide (NOP) receptor, σ receptors, and cannabinoid receptors. Several examples of bifunctional analgesics in preclinical and clinical development are highlighted, as are strategies being employed toward the rational design of novel agents.